Ventricular assist devices for circulatory support
Ask the expert
The report presents a summary of reimbursement situation for ventricular assist devices for circulatory support.
The report includes all types of the ventricular assist devices: intra-, para- and extra-corporeal. Openly and percutaneously placed devices are considered. Veno-arterial ECMO for circulatory support is not considered in this report.
Bridge-to-decision, bridge-to-transplant and destination therapy indications are considered.
The following clinical situations are considered: deterioration of chronic advanced heart failure, post-cardiotomy cardiogenic shock, post-myocardial infarction cardiogenic shock.
The only reimbursement within public / statutory health insurance systems is considered.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
Manufacturers of ventricular assist devices for circulatory support include:
- Abbott (CentriMag, Thoratec PVAD, HeartMate PHP, PediVas, Heartmate II left ventricular assist system, Heartmate III left ventricular assist system)
- Abiomed Inc. (Impella)
- Berlin Heart (EXCOR ADULT, Incor)
- Jarvik Heart (Jarvik 2000)
- LaunchPoint Technologies Inc. (Streamliner VAD)
- LivaNova (TandemHeart)
- Medtronic (BPX-80 BIO-Pump Plus, HeartWare HVAD System)
- MITIheart (MTIHeartLVAD)
- ReliantHeart (HeartAssist5)
- Ventracor (VentrAssist)
- Xenios (Icor)
Table of content is not available at the moment.
New material codes for Ventricular Assist Device and Aortic Endoprotheses were added to the List of reimbursable devices of the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) in April 2018.Read more
In December, HAS published a set of decisions about add-on reimbursement of medical devices that were evaluated by the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS). These decisions concern respiratory prostheses for total laryngectomy, mandibular advancement devices, some cardiovascular devices (transcutaneous bioprosthetic aortic heart valve, ventricular assist device, etc.) and other devices.Read more
In the first half of 2017, Galician Agency for Health Technology Assessment (AVALIA-T) published 4 HTAs for medical technologies and procedures including Impella ventricular assist device in cardiogenic shock, microwave ablation for tumors of the liver, microsurgery in limb lymphedema and intravitreal injections. Read high-level conclusions from these assessments.Read more
Recently, CNEDiMTS at HAS issued positive recommendation for inclusion of HeartMate 3 ventricular assist device into add-on reimbursement catalogue (LPPR title III). No added value was established vs earlier version of device (HeartMate II), despite better safety profile demonstrated in the randomized controlled trial.Read more